ミツイシ ツヨシ
  三石 剛
   所属   医学部 医学科(附属八千代医療センター)
   職種   准教授
論文種別 原著
言語種別 英語
査読の有無 査読有り
表題 Specific substance of Maruyama (SSM) suppresses immune responses in atopic dermatitis-like skin lesions in DS-Nh mice by modulating dendritic cell functions.
掲載誌名 正式名:Journal of dermatological science
略  称:J Dermatol Sci
ISSNコード:1873-569X(Electronic)0923-1811(Linking)
巻・号・頁 63(3),184-90頁
著者・共著者 Mitsuishi Tsuyoshi, Kabashima Kenji, Tanizaki Hideaki, Ohsawa Ikuroh, Oda Fumino, Yamada Yuko, Halifu Yilinuer, Kawana Seiji, Kato Toshihiko, Iida Kazumi
発行年月 2011/09
概要 BACKGROUND:Specific substance of Maruyama (SSM) is a carcinostatic immunotherapeutic agent extracted from Mycobacterium tuberculosis. The efficacy of SSM induced interleukin(IL)-12 and IFN-γ production, and inhibition of IL-4, resulting in a shift from Th2 to Th1 in vivo.OBJECTIVE:The DS-Nh mice are a model of human atopic dermatitis (AD), which spontaneously develop dermatitis under conventional conditions. In this study, to determine whether SSM can prevent the development of skin lesions in a murine model of AD.METHODS:DS-Nh mice were injected with SSM 5 days per week for 11 weeks. Pharmacological, histological and serological studies were performed to investigate the therapeutic effect of SSM for DS-Nh mice. Analysis of cytokines responses to SSM using quantitative RT-PCR and flow cytometry were also performed to evaluate their therapeutic mechanisms in these AD model mice.RESULTS:Clinically, erythema, erosions, excoriation, and edema were observed in DS-Nh mice at 16 weeks of age, which advanced with age. Histologically, the relative number of mast cells increased in DS-Nh mice. SSM treatment alleviated the clinical and histological findings in accord with reduced serum IgE level, and increased IgG2a level. TSLP expression was not induced, but IL-1β, IL-12, IL-17A, and IFN-γ were induced in SSM-treated DS-Nh mice. Overall, SSM treatments increased the number of activated DCs in lesions. SSM induced CD80, CD86, and MHC class II expression on bone marrow-derived DCs.CONCLUSIONS:SSM enhanced IL-12 production, but suppressed TSLP expression, resulting in a shift from Th2 to Th1 responses. This shift suppressed AD-like skin lesions in a similar fashion as the BCG vaccine. Therefore, SSM may be a useful adjuvant for suppressing skin lesions in AD models.
DOI 10.1016/j.jdermsci.2011.05.007
文献番号 21708453